This project focuses on the establishment of a new class of natural proteins as therapeutics for treatment of cancers.
Specific aims for the next period focus on providing a solid foundation for advancing a first-in-class biologic into human clinical trials for treatment of malignant melanoma. The application is based on the novel, expanded function of an activated form of a human tRNA synthetase and its applications to oncology. The synthetases (one for each amino acid) are ancient, universal proteins that catalyze attachment (aminoacylation) of each amino acid to its cognate tRNA in the first step of protein synthesis. We focused on the ex-translational function of a specific tRNA synthetase-tryptophanyl tRNA synthetase--where physiological relevance is clear. A naturally produced alternative form of human TrpRS, named as TrpRSAct, has potent anti-angiogenic activity through a mechanism that has been worked out in some detail. In particular, it blocks the assembly of new blood vessels and simultaneously inhibits activation of genes associated with angiogenesis. Because it inhibits new blood vessel formation, with no disruption of existing blood vessels, TrpRSAct has appeal for therapeutic applications to oncology. In addition to its strong anti-angiogenic properties, preliminary work showed that exogenously provided TrpRSAct activates destruction of a cellular protein that is involved in the etiology of many cancers, and is the target of new anti-cancer therapeutics. Preliminary work showed a strong therapeutic response to TrpRSAct when administered to mice bearing two different melanomas. The concepts and new treatments that emerge from this work are intended to change and expand the perspective and vision of investigators who focus on developing new approaches to cancer treatment. Specifically, while virtually all approaches to cancer therapies rely on small molecule chemotherapeutics or monoclonal antibodies, the proposed work introduces an entirely new first-in-class therapeutic protein. In addition, because the mechanism of action of TrpRSAct is distinct from those of the approved chemotherapeutics or monoclonal antibodies, it may be used in combination with existing therapeutics. Preliminary studies show strong activity of TrpRSAct when used alone, or in combination with a chemical agent. This success of the combination is doubtless because the mechanism of action of TrpRSAct is different. Thus, beyond the use by itself, TrpRSAct could lead to many new and expanded combination therapies.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA092577-12
Application #
8462920
Study Section
Vascular Cell and Molecular Biology Study Section (VCMB)
Program Officer
Knowlton, John R
Project Start
2001-07-01
Project End
2017-03-31
Budget Start
2013-04-01
Budget End
2014-03-31
Support Year
12
Fiscal Year
2013
Total Cost
$281,377
Indirect Cost
$132,893
Name
Scripps Research Institute
Department
Type
DUNS #
781613492
City
La Jolla
State
CA
Country
United States
Zip Code
92037
Wei, Zhiyi; Xu, Zhiwen; Liu, Xiaotian et al. (2016) Alternative splicing creates two new architectures for human tyrosyl-tRNA synthetase. Nucleic Acids Res 44:1247-55
Song, Youngzee; Shi, Yi; Carland, Tristan M et al. (2016) p53-Dependent DNA damage response sensitive to editing-defective tRNA synthetase in zebrafish. Proc Natl Acad Sci U S A 113:8460-5
Sun, Litao; Song, Youngzee; Blocquel, David et al. (2016) Two crystal structures reveal design for repurposing the C-Ala domain of human AlaRS. Proc Natl Acad Sci U S A 113:14300-14305
Fisch, Kathleen M; Meißner, Tobias; Gioia, Louis et al. (2015) Omics Pipe: a community-based framework for reproducible multi-omics data analysis. Bioinformatics 31:1724-8
Herman, Jonathan D; Pepper, Lauren R; Cortese, Joseph F et al. (2015) The cytoplasmic prolyl-tRNA synthetase of the malaria parasite is a dual-stage target of febrifugine and its analogs. Sci Transl Med 7:288ra77
Sajish, Mathew; Schimmel, Paul (2015) A human tRNA synthetase is a potent PARP1-activating effector target for resveratrol. Nature 519:370-3
Zhou, Jie J; Wang, Feng; Xu, Zhiwen et al. (2014) Secreted histidyl-tRNA synthetase splice variants elaborate major epitopes for autoantibodies in inflammatory myositis. J Biol Chem 289:19269-75
Liu, Ye; Satz, Jakob S; Vo, My-Nuong et al. (2014) Deficiencies in tRNA synthetase editing activity cause cardioproteinopathy. Proc Natl Acad Sci U S A 111:17570-5
Lo, Wing-Sze; Gardiner, Elisabeth; Xu, Zhiwen et al. (2014) Human tRNA synthetase catalytic nulls with diverse functions. Science 345:328-32
Klipcan, Liron; Safro, Mark; Schimmel, Paul (2013) Anticodon G recognition by tRNA synthetases mimics the tRNA core. Trends Biochem Sci 38:229-32

Showing the most recent 10 out of 41 publications